Harvard Bioscience reports Q3 2026 revenue up 8% but margin compression
Harvard Bioscience announced third‑quarter 2026 revenue of $22.2 million, an 8% year‑over‑year increase driven by demand in Asia‑Pacific and contract‑research organizations. Gross margin fell to 55.4% on a GAAP basis and 57.1% on an adjusted basis, reflecting a higher mix of lower‑margin legacy products and expanded distribution in China, where revenue grew 31%. The company reaffirmed full‑year revenue guidance of 3%‑5% growth, projected Q4 revenue of $23.7‑$25.5 million, and said its Project Viking consolidation plan remains on track to generate $3 million in cost savings in 2027, rising to $4 million annually thereafter.
Why it matters
The earnings release shows top‑line growth but pressure on profitability, which may affect investor sentiment and valuation. The reaffirmed revenue guidance and upcoming cost‑saving initiative provide a clearer outlook for Q4 and 2027, potentially supporting the stock price. Management’s margin targets of 59%‑61% for Q4 indicate a path to improve profitability if the cost‑saving plan succeeds.
Key facts
- 1Q3 2026 revenue was $22.2 million, up 8% from $20.6 million in the prior year. investing.com
- 2GAAP gross margin was 55.4% and adjusted gross margin was 57.1%, down from 59.2% adjusted in Q3 2025. investing.com
- 3Adjusted EBITDA for the quarter was $1.8 million. finance.yahoo.com
- 4Net debt increased to $35.1 million from $27.5 million a year earlier. investing.com
- 5Cash and cash equivalents at quarter end were $4.9 million. investing.com
- 6Revenue in China grew 31% year‑over‑year. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.